BRNS vs BNTX

For growth investors, BioNTech SE (BNTX) is the stronger pick with 0.

2% revenue growth year-over-year, versus -100. 0% for Barinthus Biotherapeutics plc (BRNS). Analysts rate BioNTech SE (BNTX) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, BioNTech SE (BNTX) delivered a total return of -42.

0%, compared to -95. 3% for Barinthus Biotherapeutics plc (BRNS). Over 10 years, the gap is even starker: BNTX returned +583. 8% versus BRNS's -95. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BioNTech SE (BNTX) is the lower-risk stock at 1.

14β versus Barinthus Biotherapeutics plc's 1. 28β — meaning BRNS is approximately 12% more volatile than BNTX relative to the S&P 500. On balance sheet safety, BioNTech SE (BNTX) carries a lower debt/equity ratio of 1% versus 15% for Barinthus Biotherapeutics plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), BioNTech SE (BNTX) is pulling ahead at 0.

2% versus -100. 0% for Barinthus Biotherapeutics plc (BRNS). On earnings-per-share growth, the picture is similar: Barinthus Biotherapeutics plc grew EPS -5. 8% year-over-year, compared to -62. 8% for BioNTech SE. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Barinthus Biotherapeutics plc (BRNS) is the more profitable company, earning 0.

0% net margin versus -39. 6% for BioNTech SE — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BRNS leads at 0. 0% versus -22. 6% for BNTX. At the gross margin level — before operating expenses — BNTX leads at 77. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, BioNTech SE (BNTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

14), +583. 8% 10Y return). Both have compounded well over 10 years (BNTX: +583. 8%, BRNS: -95. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.